The Effect of Advanced Glycation End Products (AGEs) on Human Umbilical Cord Mesenchymal Stem Cells (hUCMSCs) with regard to Osteogenesis and Calcification

Background: Diabetes Mellitus is a systemic disease characterized by an increase in blood glucose which, in the long term, enhances advanced glycation end product and leads to impaired osteogenesis. In prosthodontics, the osteogenic process plays an important role in successful treatment. Purpose: T...

Full description

Saved in:
Bibliographic Details
Published in:Research journal of pharmacy and technology 2021-08, Vol.14 (8), p.4019-4024
Main Authors: Kuntjoro, Mefina, Agustono, Bambang, Prasetyo, Eric Priyo, Salim, Sherman, Rantam, Fedik Abdul, Hendrijantini, Nike
Format: Article
Language:English
Subjects:
Age
Antibodies
Calcification
Diabetes
Ethics
Gene expression
Laboratories
Medical research
Mineralization
Osteoporosis
Oxidative stress
R&D
Research & development
Stem cells
Transplants & implants
Umbilical cord
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Diabetes Mellitus is a systemic disease characterized by an increase in blood glucose which, in the long term, enhances advanced glycation end product and leads to impaired osteogenesis. In prosthodontics, the osteogenic process plays an important role in successful treatment. Purpose: The purpose of this study is to determine the effect of Advanced Glycation End products (AGEs) present in Human Umbilical Cord Mesenchymal Stem Cells (hUCMSCs) on osteogenesis and calcification. Materials and Methods: MSCs isolated from human umbilical cord were cultured and underwent expansion up to passage 5. The research sample was divided into two sub-groups; a treatment group (osteogenic medium+AGE-BSA medium) and a control group (osteogenic medium) each of which underwent three replications. Samples were examined immunocytochemically on days 1, 3, 7, 8, 9, 12, 14 and 21 to quantify the level of RUNX2 expression. Alizarin red staining was performed on day 21. Results: In the treatment group, RUNX2 expression increased on day 3, reaching a peak on days 7 and 14. That expression decreased on day 8. In the control group, the expression of RUNX2 reached its peak on day 8 before decreasing on day 9. The presence of alizarin red indicated calcification in the control medium, but less mineralization in the treatment group. Conclusion: The research indicated that AGE-BSA enhances the production of RUNX2 expression in hUCMSCs at both the initial and maturation stages. This finding was supported by the results of alizarin red staining which indicated that increased levels of RUNX2 produced less mineralization.
ISSN:0974-3618
0974-360X
0974-306X
DOI:10.52711/0974-360X.2021.00696